1. Clinical Efficacy and Safety of Fanhdi®, a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study. (February 2022) Authors: Jiménez-Yuste, Víctor; Alvarez-Román, María Teresa; Palomo Bravo, Ángeles; Galmes, Bernardo J.; Nieto Hernández, Maria del Mar; Benítez Hidalgo, Olga; Marzo Alonso, Cristina; Pérez González, Noelia Florencia; Coll, Julia; Núñez, Ramiro; Carrasco, Marina; García Candel, Faustino; Gonzalez-Porras, ... Journal: Clinical and applied thrombosis/hemostasis Issue: Volume 28(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Derivation of a Pharmacokinetic Model to Include a Plasma-Derived, von Willebrand Factor-Containing Factor VIII (Koate®-DVI) Concentrate and its Low-Dose Use. (November 2021) Authors: Hajducek, Dagmar M.; Primacakti, Fitri; Chozie, Novie; Mir, Roser; McEneny-King, Alanna; Iorio, Alfonso; Edginton, Andrea Journal: Plasmatology Issue: Volume 15(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild‐type ovarian cancer cells. Issue 7 (11th October 2012) Authors: Mir, Roser; Tortosa, Avelina; Martinez‐Soler, Fina; Vidal, August; Condom, Enric; Pérez‐Perarnau, Alba; Ruiz‐Larroya, Tatiana; Gil, Joan; Giménez‐Bonafé, Pepita Journal: International journal of cancer Issue: Volume 132:Issue 7(2013:Apr. 01) Page Start: 1525 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗